management in evaluating the performance of
Schering-Plough's overall business. The effects of purchase accounting
adjustments, special and acquisition-related items and other specified
items have been excluded from Net income available to common shareholders
and Diluted earnings per common share as management of Schering-Plough does
not consider these items to be indicative of continuing operating results.
Schering-Plough believes that these "As Reconciled" performance measures
contribute to a more complete understanding by investors of the overall
results of the company and enhances investor understanding of items that
impact the comparability of results between fiscal periods. Net income
available to common shareholders and Diluted earnings per common share, as
reported, are required to be presented under U.S. GAAP.
Three months ended September 30, 2008
(unaudited)
-------------------------------------------------------
Special and
Purchase Acquisition- Other As
As Accounting Related Specified Reconciled
Reported Adjustments Items Items (1)
-------------------------------------------------------
Net sales $4,576 $- $- $- $4,576
Cost of sales 1,737 (221) - - 1,516
Selling, general
and administrative 1,660 (1) - - 1,659
Research and
development 893 (3) - - 890
Other expense/
(income), net (39) - - 160 121
Special and
acquisition-related
charges 101 - (101) - -
'/>"/>SOURCE Schering-Plough Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Related medicine news :1.
Schering-Plough Announces Transition of Animal Health Leadership2.
Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture3.
Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck4.
Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 20175.
Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia6.
Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management7.
Schering-Plough to Webcast Presentation by CEO Fred Hassan at Lehman Brothers Eleventh Annual Global Healthcare Conference8.
Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain9.
CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough10.
Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough11.
Schering-Plough CEO to Buy $2 Million in Common Shares